Paolo Di Giorgio

Paolo Di Giorgio has extensive experience in the biotechnology and pharmaceutical industries. Paolo is currently serving as the Chief Executive Officer & Managing Director at Angelini Ventures. Previously, they held leadership positions at Angelini Pharma as the Head of Angelini Pharma Ventures and External Innovation, and the Head of Research and Development. Paolo has also worked at Novartis, where they contributed to business development and led neuroscience projects as a project team leader and laboratory head. Prior to that, they conducted research as a Postdoctoral Fellow at the Salk Institute for Biological Studies and completed their PhD at Harvard University, focusing on neurodegenerative diseases. Paolo Di Giorgio has also held various board and observer roles at companies such as Arclight Therapeutics, GenEp, Pretzel Therapeutics, ARGOBIO, and served as a member of the Investment committee at Angelini Lumira Bioscience Fund (ALBF).

Paolo Di Giorgio holds a Doctor of Philosophy (Ph.D.) degree in Cellular and Molecular Biology from Harvard University, obtained in 2007. Paolo also completed a Bachelor's degree in Biotechnology from Alma Mater Studiorum – Università di Bologna in 2001. In 2014, they pursued a Master of Business Administration (M.B.A.) degree at IE Business School, which was completed in 2015.